Session of 1999
         
SENATE BILL No. 193
         
By Committee on Public Health and Welfare
         
2-1
         

  9             AN  ACT concerning the prescribing of drugs by physicians' assistants;
10             amending K.S.A. 65-2896e and K.S.A. 1998 Supp. 65-1626 and 65-
11             4101 and repealing the existing sections.
12      
13       Be it enacted by the Legislature of the State of Kansas:
14             Section  1. K.S.A. 1998 Supp. 65-1626 is hereby amended to read as
15       follows: 65-1626. For the purposes of this act:
16             (a) "Administer" means the direct application of a drug, whether by
17       injection, inhalation, ingestion or any other means, to the body of a patient
18       or research subject by:
19             (1) A practitioner or pursuant to the lawful direction of a practitioner,
20       or
21             (2) the patient or research subject at the direction and in the presence
22       of the practitioner.
23             (b) "Agent" means an authorized person who acts on behalf of or at
24       the direction of a manufacturer, distributor or dispenser but shall not
25       include a common or contract carrier, public warehouseman or employee
26       of the carrier or warehouseman when acting in the usual and lawful course
27       of the carrier's or warehouseman's business.
28             (c) "Board" means the state board of pharmacy created by K.S.A. 74-
29       1603 and amendments thereto.
30             (d) "Brand exchange" means the dispensing of a different drug prod-
31       uct of the same dosage form and strength and of the same generic name
32       than the brand name drug product prescribed.
33             (e) "Brand name" means the registered trademark name given to a
34       drug product by its manufacturer, labeler or distributor.
35             (f) "Deliver" or "delivery" means the actual, constructive or at-
36       tempted transfer from one person to another of any drug whether or not
37       an agency relationship exists.
38             (g) "Direct supervision" means the process by which the responsible
39       pharmacist shall observe and direct the activities of a pharmacy student
40       or pharmacy technician to a sufficient degree to assure that all such ac-
41       tivities are performed accurately, safely and without risk or harm to pa-
42       tients, and complete the final check before dispensing.
43             (h) "Dispense" means to deliver prescription medication to the ulti-
44       mate user or research subject by or pursuant to the lawful order of a
45       practitioner.
46             (i) "Dispenser" means a practitioner or pharmacist who dispenses
47       prescription medication.
48             (j) "Distribute" means to deliver, other than by administering or dis-
49       pensing, any drug.
50             (k) "Distributor" means a person who distributes a drug.
51             (l) "Drug" means: (1) Articles recognized in the official United States
52       pharmacopoeia, or other such official compendiums of the United States,
53       or official national formulary, or any supplement of any of them; (2) ar-
54       ticles intended for use in the diagnosis, cure, mitigation, treatment or
55       prevention of disease in man or other animals; (3) articles, other than
56       food, intended to affect the structure or any function of the body of man
57       or other animals; and (4) articles intended for use as a component of any
58       articles specified in clause (1), (2) or (3) of this subsection; but does not
59       include devices or their components, parts or accessories, except that the
60       term "drug" shall not include amygdalin (laetrile) or any livestock remedy,
61       as defined in K.S.A. 47-501 and amendments thereto, if such livestock
62       remedy has been registered in accordance with the provisions of article
63       5 of chapter 47 of the Kansas Statutes Annotated.
64             (m) "Electronic transmission" means transmission of information in
65       electronic form or the transmission of the exact visual image of a docu-
66       ment by way of electronic equipment.
67             (n) "Generic name" means the established chemical name or official
68       name of a drug or drug product.
69             (o)  (1) "Institutional drug room" means any location where prescrip-
70       tion-only drugs are stored and from which prescription-only drugs are
71       administered or dispensed and which is maintained or operated for the
72       purpose of providing the drug needs of:
73             (A) Inmates of a jail or correctional institution or facility;
74             (B) residents of a juvenile detention facility, as defined by the Kansas
75       code for care of children and the Kansas juvenile justice code;
76             (C) students of a public or private university or college, a community
77       college or any other institution of higher learning which is located in
78       Kansas; or
79             (D) employees of a business or other employer.
80             (2) "Institutional drug room" does not include:
81             (A) Any registered pharmacy;
82             (B) any office of a practitioner; or
83             (C) a location where no prescription-only drugs are dispensed and no
84       prescription-only drugs other than individual prescriptions are stored or
85       administered.
86             (p) "Medical care facility" shall have the meaning provided in K.S.A.
87       65-425 and amendments thereto, except that the term shall also include
88       facilities licensed under the provisions of K.S.A. 75-3307b and amend-
89       ments thereto except community mental health centers and facilities for
90       the mentally retarded.
91             (q) "Manufacture" means the production, preparation, propagation,
92       compounding, conversion or processing of a drug either directly or in-
93       directly by extraction from substances of natural origin, independently by
94       means of chemical synthesis or by a combination of extraction and chem-
95       ical synthesis and includes any packaging or repackaging of the drug or
96       labeling or relabeling of its container, except that this term shall not in-
97       clude the preparation or compounding of a drug by an individual for the
98       individual's own use or the preparation, compounding, packaging or la-
99       beling of a drug by: (1) A practitioner or a practitioner's authorized agent
100       incident to such practitioner's administering or dispensing of a drug in
101       the course of the practitioner's professional practice; (2) a practitioner,
102       by a practitioner's authorized agent or under a practitioner's supervision
103       for the purpose of, or as an incident to, research, teaching or chemical
104       analysis and not for sale; or (3) a pharmacist or the pharmacist's author-
105       ized agent acting under the direct supervision of the pharmacist for the
106       purpose of, or incident to, the dispensing of a drug by the pharmacist.
107             (r) "Person" means individual, corporation, government, govern-
108       mental subdivision or agency, partnership, association or any other legal
109       entity.
110             (s) "Pharmacist" means any natural person licensed under this act to
111       practice pharmacy.
112             (t) "Pharmacist in charge" means the pharmacist who is responsible
113       to the board for a registered establishment's compliance with the laws
114       and regulations of this state pertaining to the practice of pharmacy, man-
115       ufacturing of drugs and the distribution of drugs. The pharmacist in
116       charge shall supervise such establishment on a full-time or a part-time
117       basis and perform such other duties relating to supervision of a registered
118       establishment as may be prescribed by the board by rules and regulations.
119       Nothing in this definition shall relieve other pharmacists or persons from
120       their responsibility to comply with state and federal laws and regulations.
121             (u) "Pharmacy," "drug store" or "apothecary" means premises, lab-
122       oratory, area or other place: (1) Where drugs are offered for sale where
123       the profession of pharmacy is practiced and where prescriptions are com-
124       pounded and dispensed; or (2) which has displayed upon it or within it
125       the words "pharmacist," "pharmaceutical chemist," "pharmacy," "apoth-
126       ecary," "drugstore," "druggist," "drugs," "drug sundries" or any of these
127       words or combinations of these words or words of similar import either
128       in English or any sign containing any of these words; or (3) where the
129       characteristic symbols of pharmacy or the characteristic prescription sign
130       "Rx" may be exhibited. As used in this subsection, premises refers only
131       to the portion of any building or structure leased, used or controlled by
132       the licensee in the conduct of the business registered by the board at the
133       address for which the registration was issued.
134             (v) "Pharmacy student" means an individual, registered with the
135       board of pharmacy, enrolled in an accredited school of pharmacy.
136             (w) "Pharmacy technician" means an individual who, under the direct
137       supervision and control of a pharmacist, may perform packaging, manip-
138       ulative, repetitive or other nondiscretionary tasks related to the processing
139       of a prescription or medication order and who assists the pharmacist in
140       the performance of pharmacy related duties, but who does not perform
141       duties restricted to a pharmacist.
142             (x) "Practitioner" means a person licensed to practice medicine and
143       surgery, dentist, podiatrist, veterinarian, optometrist licensed under the
144       optometry law as a therapeutic licensee or diagnostic and therapeutic
145       licensee, or scientific investigator or other person authorized by law to
146       use a prescription-only drug in teaching or chemical analysis or to conduct
147       research with respect to a prescription-only drug.
148             (y) "Preceptor" means a licensed pharmacist who possesses at least
149       two years' experience as a pharmacist and who supervises students ob-
150       taining the pharmaceutical experience required by law as a condition to
151       taking the examination for licensure as a pharmacist.
152             (z) "Prescription" means, according to the context, either a prescrip-
153       tion order or a prescription medication.
154             (aa) "Prescription medication" means any drug, including label and
155       container according to context, which is dispensed pursuant to a prescrip-
156       tion order.
157             (bb) "Prescription-only drug" means any drug required by the federal
158       or state food, drug and cosmetic act to bear on its label the legend "Cau-
159       tion: Federal law prohibits dispensing without prescription."
160             (cc) "Prescription order" means: (1) An order to be filled by a phar-
161       macist for prescription medication issued and signed by a practitioner or
162       a mid-level practitioner in the authorized course of professional practice;
163       or (2) an order transmitted to a pharmacist through word of mouth, note,
164       telephone or other means of communication directed by such
165       practitioner.
166             (dd) "Probation" means the practice or operation under a temporary
167       license, registration or permit or a conditional license, registration or per-
168       mit of a business or profession for which a license, registration or permit
169       is granted by the board under the provisions of the pharmacy act of the
170       state of Kansas requiring certain actions to be accomplished or certain
171       actions not to occur before a regular license, registration or permit is
172       issued.
173             (ee) "Professional incompetency" means:
174             (1) One or more instances involving failure to adhere to the appli-
175       cable standard of pharmaceutical care to a degree which constitutes gross
176       negligence, as determined by the board;
177             (2) repeated instances involving failure to adhere to the applicable
178       standard of pharmaceutical care to a degree which constitutes ordinary
179       negligence, as determined by the board; or
180             (3) a pattern of pharmacy practice or other behavior which demon-
181       strates a manifest incapacity or incompetence to practice pharmacy.
182             (ff) "Retail dealer" means a person selling at retail nonprescription
183       drugs which are prepackaged, fully prepared by the manufacturer or dis-
184       tributor for use by the consumer and labeled in accordance with the
185       requirements of the state and federal food, drug and cosmetic acts. Such
186       nonprescription drugs shall not include: (1) A controlled substance; (2) a
187       drug the label of which is required to bear substantially the statement
188       "Caution: Federal law prohibits dispensing without prescription"; or (3)
189       a drug intended for human use by hypodermic injection.
190             (gg) "Secretary" means the executive secretary of the board.
191             (hh) "Unprofessional conduct" means:
192             (1) Fraud in securing a registration or permit;
193             (2) intentional adulteration or mislabeling of any drug, medicine,
194       chemical or poison;
195             (3) causing any drug, medicine, chemical or poison to be adulterated
196       or mislabeled, knowing the same to be adulterated or mislabeled;
197             (4) intentionally falsifying or altering records or prescriptions;
198             (5) unlawful possession of drugs and unlawful diversion of drugs to
199       others;
200             (6) willful betrayal of confidential information under K.S.A. 65-1654
201       and amendments thereto;
202             (7) conduct likely to deceive, defraud or harm the public;
203             (8) making a false or misleading statement regarding the licensee's
204       professional practice or the efficacy or value of a drug;
205             (9) commission of any act of sexual abuse, misconduct or exploitation
206       related to the licensee's professional practice; or
207             (10)  performing unnecessary tests, examinations or services which
208       have no legitimate pharmaceutical purpose.
209             (ii) "Mid-level practitioner" means a practitioner other than those
210       defined in K.S.A. 65-1626 and 65-4101 and amendments thereto who has
211       authority to prescribe drugs under K.S.A. 65-2896e and amendments
212       thereto.
213             Sec.  2. K.S.A. 65-2896e is hereby amended to read as follows: 65-
214       2896e. (a) A person whose name has been entered on the register of
215       physicians' assistants may perform, only under the direction and super-
216       vision of a physician, acts which constitute the practice of medicine and
217       surgery to the extent and in the manner authorized by the physician re-
218       sponsible for the physician's assistant and only to the extent such acts are
219       consistent with rules and regulations adopted by the board which relate
220       to acts performed by a physician's assistant under the responsible physi-
221       cian's direction and supervision. A physician's assistant may not prescribe
222       drugs but may transmit a prescription order for drugs pursuant to a writ-
223       ten protocol as authorized by the responsible physician. Before a physi-
224       cian's assistant shall perform under the direction and supervision of a
225       physician, such physician's assistant shall be identified to the patient and
226       others involved in providing the patient services as a physician's assistant
227       to the responsible physician. A physician's assistant may not perform any
228       act or procedure performed in the practice of optometry except as pro-
229       vided in K.S.A. 65-1508 and 65-2887 and amendments thereto.
230             (b) The board shall adopt rules and regulations governing the trans-
231       mitting of prescription orders for prescribing of drugs by physicians' as-
232       sistants and the responsibilities of the responsible physician with respect
233       thereto. Such rules and regulations shall establish such conditions and
234       limitations as the board determines to be necessary to protect the public
235       health and safety. In developing rules and regulations relating to the trans-
236       mitting of prescription orders for prescribing of drugs by physicians' as-
237       sistants, the board shall take into consideration the amount of training
238       and capabilities of physicians' assistants, the different practice settings in
239       which physicians' assistants and responsible physicians practice, the de-
240       gree of direction and supervision to be provided by a responsible physi-
241       cian and the needs of the geographic area of the state in which the phy-
242       sician's assistant and the responsible physician practice. In all cases in
243       which a physician's assistant is authorized to transmit prescription orders
244       for prescribe drugs by a responsible physician, a written protocol between
245       the responsible physician and the physician's assistant containing the es-
246       sential terms of such authorization shall be in effect. In no case shall the
247       scope of the authority of the physician's assistant to transmit prescription
248       orders for prescribe drugs exceed the normal and customary practice of
249       the responsible physician in the prescribing of drugs.
250             (c) The physician's assistant may not dispense drugs, but may request,
251       receive and sign for professional samples and may distribute professional
252       samples to patients. In order to prescribe controlled substances, the phy-
253       sician's assistant shall register with the federal drug enforcement
254       administration.
255             (d) As used in this section, "drug" means those articles and substances
256       defined as drugs in K.S.A. 65-1626 and 65-4101 and amendments thereto.
257             Sec.  3. K.S.A. 1998 Supp. 65-4101 is hereby amended to read as
258       follows: 65-4101. As used in this act: (a) "Administer" means the direct
259       application of a controlled substance, whether by injection, inhalation,
260       ingestion or any other means, to the body of a patient or research subject
261       by: (1) A practitioner or pursuant to the lawful direction of a practitioner;
262       or
263             (2) the patient or research subject at the direction and in the presence
264       of the practitioner.
265             (b) "Agent" means an authorized person who acts on behalf of or at
266       the direction of a manufacturer, distributor or dispenser. It does not in-
267       clude a common or contract carrier, public warehouseman or employee
268       of the carrier or warehouseman.
269             (c) "Board" means the state board of pharmacy.
270             (d) "Bureau" means the bureau of narcotics and dangerous drugs,
271       United States department of justice, or its successor agency.
272             (e) "Controlled substance" means any drug, substance or immediate
273       precursor included in any of the schedules designated in K.S.A. 65-4105,
274       65-4107, 65-4109, 65-4111 and 65-4113, and amendments to these
275       sections.
276             (f) "Counterfeit substance" means a controlled substance which, or
277       the container or labeling of which, without authorization bears the trade-
278       mark, trade name or other identifying mark, imprint, number or device
279       or any likeness thereof of a manufacturer, distributor or dispenser other
280       than the person who in fact manufactured, distributed or dispensed the
281       substance.
282             (g) "Deliver" or "delivery" means the actual, constructive or at-
283       tempted transfer from one person to another of a controlled substance,
284       whether or not there is an agency relationship.
285             (h) "Dispense" means to deliver a controlled substance to an ultimate
286       user or research subject by or pursuant to the lawful order of a practi-
287       tioner, including the packaging, labeling or compounding necessary to
288       prepare the substance for that delivery.
289             (i) "Dispenser" means a practitioner or pharmacist who dispenses.
290             (j) "Distribute" means to deliver other than by administering or dis-
291       pensing a controlled substance.
292             (k) "Distributor" means a person who distributes.
293             (l) "Drug" means: (1) Substances recognized as drugs in the official
294       United States pharmacopoeia, official homeopathic pharmacopoeia of the
295       United States or official national formulary or any supplement to any of
296       them; (2) substances intended for use in the diagnosis, cure, mitigation,
297       treatment or prevention of disease in man or animals; (3) substances
298       (other than food) intended to affect the structure or any function of the
299       body of man or animals; and (4) substances intended for use as a com-
300       ponent of any article specified in clause (1), (2) or (3) of this subsection.
301       It does not include devices or their components, parts or accessories.
302             (m) "Immediate precursor" means a substance which the board has
303       found to be and by rule and regulation designates as being the principal
304       compound commonly used or produced primarily for use and which is
305       an immediate chemical intermediary used or likely to be used in the
306       manufacture of a controlled substance, the control of which is necessary
307       to prevent, curtail or limit manufacture.
308             (n) "Manufacture" means the production, preparation, propagation,
309       compounding, conversion or processing of a controlled substance either
310       directly or indirectly by extraction from substances of natural origin or
311       independently by means of chemical synthesis or by a combination of
312       extraction and chemical synthesis and includes any packaging or repack-
313       aging of the substance or labeling or relabeling of its container, except
314       that this term does not include the preparation or compounding of a
315       controlled substance by an individual for the individual's own use or the
316       preparation, compounding, packaging or labeling of a controlled sub-
317       stance: (1) By a practitioner or the practitioner's agent pursuant to a lawful
318       order of a practitioner as an incident to the practitioner's administering
319       or dispensing of a controlled substance in the course of the practitioner's
320       professional practice; or
321             (2) by a practitioner or by the practitioner's authorized agent under
322       such practitioner's supervision for the purpose of or as an incident to
323       research, teaching or chemical analysis or by a pharmacist or medical care
324       facility as an incident to dispensing of a controlled substance.
325             (o) "Marijuana" means all parts of all varieties of the plant Cannabis
326       whether growing or not, the seeds thereof, the resin extracted from any
327       part of the plant and every compound, manufacture, salt, derivative, mix-
328       ture or preparation of the plant, its seeds or resin. It does not include the
329       mature stalks of the plant, fiber produced from the stalks, oil or cake
330       made from the seeds of the plant, any other compound, manufacture,
331       salt, derivative, mixture or preparation of the mature stalks, except the
332       resin extracted therefrom, fiber, oil, or cake or the sterilized seed of the
333       plant which is incapable of germination.
334             (p) "Narcotic drug" means any of the following whether produced
335       directly or indirectly by extraction from substances of vegetable origin or
336       independently by means of chemical synthesis or by a combination of
337       extraction and chemical synthesis: (1) Opium and opiate and any salt,
338       compound, derivative or preparation of opium or opiate;
339             (2) any salt, compound, isomer, derivative or preparation thereof
340       which is chemically equivalent or identical with any of the substances
341       referred to in clause (1) but not including the isoquinoline alkaloids of
342       opium;
343             (3) opium poppy and poppy straw;
344             (4) coca leaves and any salt, compound, derivative or preparation of
345       coca leaves, and any salt, compound, isomer, derivative or preparation
346       thereof which is chemically equivalent or identical with any of these sub-
347       stances, but not including decocainized coca leaves or extractions of coca
348       leaves which do not contain cocaine or ecgonine.
349             (q) "Opiate" means any substance having an addiction-forming or
350       addiction-sustaining liability similar to morphine or being capable of con-
351       version into a drug having addiction-forming or addiction-sustaining lia-
352       bility. It does not include, unless specifically designated as controlled
353       under K.S.A. 65-4102 and amendments thereto, the dextrorotatory iso-
354       mer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan).
355       It does include its racemic and levorotatory forms.
356             (r) "Opium poppy" means the plant of the species Papaver somni-
357       ferum l. except its seeds.
358             (s) "Person" means individual, corporation, government, or govern-
359       mental subdivision or agency, business trust, estate, trust, partnership or
360       association or any other legal entity.
361             (t) "Poppy straw" means all parts, except the seeds, of the opium
362       poppy, after mowing.
363             (u) "Pharmacist" means an individual currently licensed by the board
364       to practice the profession of pharmacy in this state.
365             (v) "Practitioner" means a person licensed to practice medicine and
366       surgery, dentist, podiatrist, veterinarian, optometrist licensed under the
367       optometry law as a therapeutic licensee or diagnostic and therapeutic
368       licensee, or scientific investigator or other person authorized by law to
369       use a controlled substance in teaching or chemical analysis or to conduct
370       research with respect to a controlled substance.
371             (w) "Production" includes the manufacture, planting, cultivation,
372       growing or harvesting of a controlled substance.
373             (x) "Ultimate user" means a person who lawfully possesses a con-
374       trolled substance for such person's own use or for the use of a member
375       of such person's household or for administering to an animal owned by
376       such person or by a member of such person's household.
377             (y) "Isomer" means all enantiomers and diastereomers.
378             (z) "Medical care facility" shall have the meaning ascribed to that
379       term in K.S.A. 65-425 and amendments thereto.
380             (aa) "Cultivate" means the planting or promotion of growth of five
381       or more plants which contain or can produce controlled substances.
382             (bb) (1) "Controlled substance analog" means a substance the chem-
383       ical structure of which is substantially similar to the chemical structure of
384       a controlled substance listed in or added to the schedules designated in
385       K.S.A. 65-4105 or 65-4107 and amendments thereto; and:
386             (A) Which has a stimulant, depressant or hallucinogenic effect on the
387       central nervous system substantially similar to the stimulant, depressant
388       or hallucinogenic effect on the central nervous system of a controlled
389       substance included in the schedules designated in K.S.A. 65-4105 or 65-
390       4107 and amendments thereto; or
391             (B) with respect to a particular individual, which the individual rep-
392       resents or intends to have a stimulant, depressant or hallucinogenic effect
393       on the central nervous system substantially similar to the stimulant, de-
394       pressant or hallucinogenic effect on the central nervous system of a con-
395       trolled substance included in the schedules designated in K.S.A. 65-4105
396       or 65-4107 and amendments thereto.
397             (2) "Controlled substance analog" does not include:
398             (A) A controlled substance;
399             (B) a substance for which there is an approved new drug application;
400             (C) a substance with respect to which an exemption is in effect for
401       investigational use by a particular person under section 505 of the federal
402       food, drug, and cosmetic act (21 U.S.C. 355) to the extent conduct with
403       respect to the substance is permitted by the exemption; or
404             (D) any substance to the extent not intended for human consumption
405       before an exemption takes effect with respect to the substance.
406             (cc) "Mid-level practitioner" means a practitioner other than those
407       defined in K.S.A. 65-1626 and 65-4101 and amendments thereto, who has
408       authority to prescribe drugs under K.S.A. 65-2896e and amendments
409       thereto.  
410       Sec.  4. K.S.A. 65-2896e and K.S.A. 1998 Supp. 65-1626 and 65-4101
411       are hereby repealed.
412        Sec.  5. This act shall take effect and be in force from and after its
413       publication in the statute book.